BRIEF—B-MS announces collaboration with Tsinghua University

Bristol-Myers Squibb (NYSE: BMY) has announced a research partnership with China's Tsinghua University, with the intent of carrying out research into fighting autoimmune diseases and cancer.

Chen Dong, immunology director at Tsinghua University, said: "As an immunology-based research institution in China, Tsinghua University continues to explore an innovative technology incubation model to transform basic research results into therapeutic drugs through strategic cooperation.

"We believe that our strengthened collaboration with B-MS will combine our respective distinguished expertise in the field of immune diseases, helping transform research discoveries into new treatment options as soon as possible."

"This collaboration with Tsinghua University is another proof of our strategic alignment with China’s innovation-driven healthcare development, as well as our commitment to accelerate delivering of innovative treatment options to Chinese patients," said Shirley Zhao, general manager and president of B-MS in mainland China and Hong Kong.